Education
About Us
Working with TipRanks
Follow Us
Bioceres Crop Solutions (BIOX)
NASDAQ:BIOX
Top Page
Bioceres Crop Solutions
(NASDAQ:BIOX)
Select Model
Select Model
Rating:62Neutral
Price Target:
$3.50
▲(75.88% Upside)
Bioceres Crop Solutions' overall score is driven by strong cash flow management and strategic initiatives highlighted in the earnings call, counterbalanced by negative technical indicators and valuation metrics. The company's financial health is underpinned by effective cash management, but profitability and revenue stability remain areas of concern.
Positive Factors
Cash Flow Improvement
Significant cash flow improvement enhances financial flexibility, reduces debt, and supports strategic investments, bolstering long-term stability.
Regulatory Approval of Rinotec
EPA approval of Rinotec enables Bioceres to expand its product offerings globally, strengthening its competitive position in biological solutions.
Growth in Seed and Integrated Products
Growth in seed and integrated products indicates strong market demand and successful product adoption, supporting future revenue expansion.
Negative Factors
Revenue Decline
A significant revenue decline highlights challenges in maintaining sales momentum, affecting the company's ability to achieve consistent growth.
Leadership Transition
CFO transition may lead to short-term disruptions in financial strategy execution, impacting the company's focus on improving financial performance.
Adjusted EBITDA Decline
Decline in adjusted EBITDA suggests pressure on profitability, necessitating cost management and efficiency improvements for sustainable growth.
Bioceres Crop Solutions (BIOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$119.78M
Dividend YieldN/A
Average Volume (3M)1.08M
Price to Earnings (P/E)―
Beta (1Y)0.51
Revenue Growth-28.28%
EPS Growth-1718.93%
CountryUS
Employees400
SectorBasic Materials
Sector Strength58
IndustryAgricultural Inputs
Share Statistics
EPS (TTM)-0.70
Shares Outstanding62,710,846
10 Day Avg. Volume1,709,433
30 Day Avg. Volume1,077,044
Financial Highlights & Ratios
PEG Ratio-2.60
Price to Book (P/B)2.23
Price to Sales (P/S)1.50
P/FCF Ratio36.94
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$11.17Price Target Upside461.31% Upside
Rating ConsensusHold
Number of Analyst Covering4
Bioceres Crop Solutions Business Overview & Revenue Model
Company DescriptionBioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through three segments: Seed and Integrated Products, Crop Protection, and Crop Nutrition. The Seed and Integrated Products segment develops and commercializes seed technology, biotechnological events, germplasm, and seed treatments. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. The company also offers HB4, a drought tolerant seed technology program. It operates in Argentina, Uruguay, France, South Africa, and internationally. The company was founded in 2001 and is headquartered in Rosario, Argentina. Bioceres Crop Solutions Corp. is a subsidiary of Bioceres LLC.
How the Company Makes MoneyBioceres Crop Solutions makes money through the sale of its agricultural biotechnology products, which include genetically modified seeds engineered for higher yields and resistance to environmental stresses. Additionally, the company generates revenue from biological inoculants that improve soil health and crop productivity, and from micro-beaded fertilizers that offer efficient nutrient delivery. Key revenue streams include direct sales to farmers and agricultural distributors. The company also benefits from strategic partnerships and collaborations with other agricultural firms and research institutions, which help in the development and distribution of its products.
Bioceres Crop Solutions Key Performance Indicators (KPIs)
Bioceres Crop Solutions Earnings Call Summary
Earnings Call Date:Sep 09, 2025
(Q4-2025)
| % Change Since: |
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant challenges faced by Bioceres Crop Solutions, particularly in Argentina, leading to a substantial decline in revenues and EBITDA. However, the company demonstrated strong cash flow generation and international sales growth, supported by cost-saving initiatives, suggesting potential stabilization and recovery in the future.Q4-2025 Updates
Positive Updates
Strong Cash Flow Generation
Despite profitability pressures, operating cash flow reached $29.9 million in the fourth quarter, up 28% year-over-year. For the full fiscal year, operating cash flow was $53 million, a 27% increase versus last year.
International Sales Growth
International sales of some core technologies grew strongly in the quarter, with adjuvant sales in Brazil almost doubling and bioprotection products in the U.S. growing almost 40%.
Cost Control Measures
The company achieved $5.7 million in savings in operating expenses due to cost control measures and plans to continue these efforts to achieve 10%-12% savings in operating expenses.
Negative Updates
Significant Revenue Decline
Fourth quarter revenues were $74.7 million, a 40% decline compared to the same period last year. Full fiscal year revenues came in at $335.3 million, down 28% year-over-year.
EBITDA Decline
Adjusted EBITDA for the quarter was negative $4.5 million, down from $19.9 million the year before. For the full fiscal year, EBITDA was $28.3 million, down from $81.4 million in '24.
Challenges in Argentina
Sales decline in Argentina due to macroeconomic shifts, including currency devaluation and adverse on-farm economics, significantly impacted revenues in all segments.
Inventory and Margin Pressure
Sales in Crop Nutrition declined by 34% for the quarter, driven by lower micro-beaded fertilizer sales in Argentina and margin compression due to pricing pressures.
Company Guidance
During the Bioceres Crop Solutions fiscal fourth quarter and full year 2025 earnings call, CEO Federico Trucco and Head of Investor Relations Paula Savanti provided key guidance metrics amidst a challenging year. The company reported a 40% decline in fourth-quarter revenues to $74.7 million, primarily due to a $25 million reduction in seed sales, with further declines in crop nutrition and crop protection. For the full fiscal year, revenues were down 28% to $335.3 million, with a consistent decrease across all segments. The gross profit for the quarter fell 47% to $25.4 million, driven by lower margins in the Crop Nutrition and Seeds segments. Despite these challenges, Bioceres focused on cash generation, achieving a 27% year-over-year increase in operating cash flow to $53 million. The company also emphasized a reduction in operating expenses by 10% to 12% and a decrease in CapEx and R&D investments by 50%, aiming for an EBITDA margin of 22% and a gross margin of 40% in future periods. The net financial debt stood at $220.8 million, with a net debt to adjusted EBITDA ratio of 7.8x. Looking forward, Bioceres aims to stabilize its financial position and leverage its biological initiatives and strategic partnerships to drive growth in less volatile agricultural markets.Bioceres Crop Solutions Financial Statement Overview
Summary
Bioceres Crop Solutions shows solid cash flow management and a strong equity base, but profitability and revenue stability are concerns. High debt levels and inconsistent profitability metrics suggest potential financial risk. Focus should be on stabilizing net income and managing leverage.Income Statement
Bioceres Crop Solutions shows volatile revenue trends with significant fluctuations in net income, indicating instability. The company has recently experienced a negative net profit margin and declining EBIT margins in TTM. Despite past growth, the current revenue trajectory suggests a need for consistency in profitability.65
Positive
Balance Sheet
The company's balance sheet shows moderate leverage with a debt-to-equity ratio that has increased over time, indicating rising financial risk. However, the equity ratio remains healthy, reflecting a strong equity position. The ROE has been inconsistent, highlighting the need for improved profitability.70
Positive
Cash Flow
The cash flow analysis indicates robust operating cash flow relative to net income in TTM, suggesting effective cash management. However, fluctuations in free cash flow growth and historical negative free cash flows point to potential liquidity concerns. The company needs to stabilize free cash flow generation.75
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 383.31M | 464.83M | 419.45M | 328.46M | 206.70M | 172.35M |
| Gross Profit | 147.41M | 181.59M | 180.25M | 126.44M | 90.88M | 79.49M |
| EBITDA | 34.95M | 55.45M | 61.09M | 40.03M | 37.04M | 29.58M |
| Net Income | -8.23M | 3.24M | 18.78M | -7.20M | -6.87M | 3.36M |
Balance Sheet | ||||||
| Total Assets | 798.21M | 850.63M | 818.06M | 518.22M | 394.59M | 297.56M |
| Cash, Cash Equivalents and Short-Term Investments | 39.35M | 56.17M | 60.05M | 38.61M | 46.78M | 51.57M |
| Total Debt | 273.30M | 270.95M | 257.41M | 169.79M | 174.58M | 149.09M |
| Total Liabilities | 453.24M | 501.06M | 487.56M | 359.92M | 304.30M | 236.81M |
| Stockholders Equity | 308.71M | 314.01M | 298.85M | 127.61M | 67.74M | 46.18M |
Cash Flow | ||||||
| Free Cash Flow | 21.32M | 18.93M | -19.97M | -26.51M | -20.13M | 4.82M |
| Operating Cash Flow | 36.36M | 41.72M | 2.59M | -17.52M | -6.21M | 9.32M |
| Investing Cash Flow | -7.91M | -28.73M | -25.73M | 2.90M | -8.31M | -7.80M |
| Financing Cash Flow | -19.67M | -10.06M | 32.95M | 14.82M | 7.36M | 33.53M |
Bioceres Crop Solutions Technical Analysis
Neutral
1.99
Price Trends
2.07
Negative
3.11
Negative
4.06
Negative
Market Momentum
-0.04
Negative
57.92
Neutral
70.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOX, the sentiment is Neutral. The current price of 1.99 is above the 20-day moving average (MA) of 1.55, below the 50-day MA of 2.07, and below the 200-day MA of 4.06, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 57.92 is Neutral, neither overbought nor oversold. The STOCH value of 70.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BIOX.
Bioceres Crop Solutions Risk Analysis
Bioceres Crop Solutions disclosed 68 risk factors in its most recent earnings report. Bioceres Crop Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Certain of the Rizobacter shares we own are subject to a judicial injunction that, if decided unfavorably to us, would require us to surrender part of our interest in Rizobacter thereby reducing our equity interest in Rizobacter. Q2, 2024
2.
The disposition or sale of our ordinary shares may be subject to taxation in Argentina. Q2, 2024
3.
Our share repurchase program may reduce liquidity. Q2, 2024
Bioceres Crop Solutions Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $119.78M | -2.42 | ― | ― | -28.28% | -1718.93% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
56 Neutral | $216.51M | ― | -973.22% | ― | 57.83% | 40.94% | |
48 Neutral | $5.32M | -0.71 | -87.18% | ― | 1.50% | -8.01% | |
46 Neutral | $12.89M | -26.96 | ― | ― | -21.82% | -104.92% | |
44 Neutral | $168.46M | ― | ― | ― | ― | ― | |
41 Neutral | $148.70M | -1.20 | -42.97% | ― | -9.57% | -3226.39% |
* Basic Materials Sector Average
BIOX
Bioceres Crop Solutions
1.99
-4.99
-71.49%
AVD
American Vanguard
5.25
-0.11
-2.05%
SEED
Origin Agritech
1.79
-1.05
-36.97%
RKDA
Arcadia Biosciences
3.92
-0.39
-9.05%
BHST
BioHarvest Sciences
11.90
7.07
146.38%
LVRO
Lavoro Limited
1.45
-2.73
-65.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.